NASDAQ:LBPS

4D pharma Stock Forecast, Price & News

$9.90

+0.20 (+2.06 %)

(As of 08/2/2021 12:00 AM ET)

Add

Compare

Today's Range

$9.90

▼

$9.92

50-Day Range

$9.00

▼

$11.97

52-Week Range

$8.97

▼

$15.50

Volume1,187 shs

Average Volume10,594 shs

Market Capitalization$162.66 million

P/E RatioN/A

Dividend YieldN/A

Beta0.04

30 days | 90 days | 365 days | Advanced Chart

Receive LBPS News and Ratings via Email

Sign-up to receive the latest news and ratings for 4D pharma and its competitors with MarketBeat's FREE daily newsletter.

About 4D pharma

4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company develops therapeutic candidates, such as MRx0518; MRx-4DP000 for the treatment of asthma and COVID-19; MRx0029 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, including MRx1299 for solid tumors, MRx0005 for neurodegeneration, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. The company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumors. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.

4D pharma Announces Two Presentations at European Society for Medical Oncology (ESMO) Congress 2021
August 2, 2021 | finance.yahoo.com

This penny stock could double in just 2 years
July 27, 2021 | fool.co.uk

4D pharma (NASDAQ:LBPS) Given Buy Rating at Chardan Capital
July 9, 2021 | americanbankingnews.com

4D pharma says pre-clinical research points to the potential of its discovery to enhance cancer CAR-T therapies
July 6, 2021 | proactiveinvestors.com

4D pharma Announces Publication of Preclinical Research Showing Single Strain Megasphaera massiliensis improves activity of CAR-T
July 6, 2021 | finance.yahoo.com

4D pharma to Participate in Ladenburg Thalmann Healthcare Conference
June 29, 2021 | finance.yahoo.com

4D pharma To Stop Testing Asthma Med in COVID-19 Patients
June 4, 2021 | feeds.benzinga.com

4D Pharma halts enrolment for Covid treatment trial, focuses on asthma
June 4, 2021 | lse.co.uk

4D pharma to Present Additional Data from Phase II Study of Blautix for the Treatment of Irritable Bowel Syndrome at Digestive Disease Week (DDW) 2021
May 17, 2021 | finance.yahoo.com

LBPS.OQ - 4d Pharma PLC Profile | Reuters
April 30, 2021 | reuters.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LBPS
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.4dpharmaplc.com
Phone44 11 3895 0130
Employees92
Year FoundedN/A

Sales & Book Value

Annual Sales$690,000.00
Price / Sales235.73
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.37 per share
Price / Book4.18

Profitability

EPS (Most Recent Fiscal Year)($2.34)
Net Income$-30,500,000.00
Net MarginsN/A
Return on Equity-4.79%
Return on Assets-1.59%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares16,430,000
Market Cap$162.66 million
Next Earnings DateN/A
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

2.03 out of 5 stars

Medical Sector

524th out of 2,226 stocks

Pharmaceutical Preparations Industry

259th out of 870 stocks

3.5 Analyst's Opinion

Consensus Rating
4D pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $37.50, 4D pharma has a forecasted upside of 278.8% from its current price of $9.90.
Amount of Analyst Coverage
4D pharma has only been the subject of 2 research reports in the past 90 days.

5.0 Community Rank

Outperform Votes
4D pharma has received 4 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
4D pharma has received 0 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
4D pharma has received 100.00% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about 4D pharma and other stocks. Vote “Outperform” if you believe LBPS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe LBPS will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
4D pharma does not currently pay a dividend.
Dividend Growth
4D pharma does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, 4D pharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
47.60% of the stock of 4D pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 1.38% of the stock of 4D pharma is held by institutions.

0.0 Earnings and Valuation

Earnings Growth
Earnings for 4D pharma are expected to decrease in the coming year, from ($0.22) to ($0.34) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of 4D pharma is -26.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of 4D pharma is -26.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
4D pharma has a P/B Ratio of 4.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

4D pharma (NASDAQ:LBPS) Frequently Asked Questions

Is 4D pharma a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 4D pharma in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" 4D pharma stock.
View analyst ratings for 4D pharma or view top-rated stocks.

What stocks does MarketBeat like better than 4D pharma?

Wall Street analysts have given 4D pharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but 4D pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for LBPS?

2 brokerages have issued 12 month price objectives for 4D pharma's shares. Their forecasts range from $35.00 to $40.00. On average, they anticipate 4D pharma's stock price to reach $37.50 in the next year. This suggests a possible upside of 278.8% from the stock's current price.
View analysts' price targets for 4D pharma or view top-rated stocks among Wall Street analysts.

Who are 4D pharma's key executives?

4D pharma's management team includes the following people:

Mr. Duncan Joseph Peyton, CEO & Exec. Director (Age 51, Pay $141.03k)
Dr. Alexander James Stevenson, Chief Scientific Officer & Exec. Director (Age 49, Pay $141.03k)
Mr. John W. Beck CPA, CPA, Chief Financial Officer (Age 61)
Fay Weston, Head of Investor Relations
Mr. Adrian Murray, Gen. Counsel (Interim)
Mr. Glenn Dourado, Chief Bus. Officer
Mr. Richard Avison, Group Fin. Director

Who are some of 4D pharma's key competitors?

Some companies that are related to 4D pharma include BioXcel Therapeutics (BTAI), AnaptysBio (ANAB), Karyopharm Therapeutics (KPTI), PyroGenesis Canada (PYR), ORIC Pharmaceuticals (ORIC), Eagle Pharmaceuticals (EGRX), Catalyst Pharmaceuticals (CPRX), Praxis Precision Medicines (PRAX), Cara Therapeutics (CARA), Gossamer Bio (GOSS), Zomedica (ZOM), Imago BioSciences (IMGO), Evolus (EOLS), Chinook Therapeutics (KDNY) and Intercept Pharmaceuticals (ICPT).
View all of LBPS's competitors.

What is 4D pharma's stock symbol?

4D pharma trades on the NASDAQ under the ticker symbol "LBPS."

Who are 4D pharma's major shareholders?

4D pharma's stock is owned by many different institutional and retail investors. Top institutional investors include Advisor Group Holdings Inc. (0.02%).

Which institutional investors are buying 4D pharma stock?

LBPS stock was bought by a variety of institutional investors in the last quarter, including Advisor Group Holdings Inc..

How do I buy shares of 4D pharma?

Shares of LBPS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is 4D pharma's stock price today?

One share of LBPS stock can currently be purchased for approximately $9.90.

How much money does 4D pharma make?

4D pharma has a market capitalization of $162.66 million and generates $690,000.00 in revenue each year. The company earns $-30,500,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis.

How many employees does 4D pharma have?

4D pharma employs 92 workers across the globe.

What is 4D pharma's official website?

The official website for 4D pharma is www.4dpharmaplc.com.

Where are 4D pharma's headquarters?

4D pharma is headquartered at 9 BOND COURT 5TH FLOOR, LEEDS X0, LS1 2JZ.

How can I contact 4D pharma?

4D pharma's mailing address is 9 BOND COURT 5TH FLOOR, LEEDS X0, LS1 2JZ. The company can be reached via phone at 44 11 3895 0130 or via email at [email protected]

This page was last updated on 8/3/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here